European Investor
05 Aug 2025, 18:37
Waters Corporation Beats Q2 Estimates, Raises 2025 Guidance
Waters Corporation (NYSE: WAT) reported strong second-quarter 2025 results, with sales rising 9% year-over-year to $771 million, surpassing expectations. Non-GAAP EPS grew 12% to $2.95, topping guidance.
Instrument sales rose mid-single digits, driven by large pharma and CDMO demand, while recurring revenue climbed 11%. Pharma revenue surged 11%, offsetting a 3% drop in Academic & Government sales.
Citing robust demand and operational strength, Waters raised full-year 2025 non-GAAP EPS guidance to $12.95–$13.05 and constant currency sales growth to 5.5%–7.5%.
CEO Udit Batra also highlighted integration plans for BD Biosciences & Diagnostic Solutions, naming Chris Ross to lead the process.
Waters Corporation (NYSE: WAT) reported strong second-quarter 2025 results, with sales rising 9% year-over-year to $771 million, surpassing expectations. Non-GAAP EPS grew 12% to $2.95, topping guidance.
Instrument sales rose mid-single digits, driven by large pharma and CDMO demand, while recurring revenue climbed 11%. Pharma revenue surged 11%, offsetting a 3% drop in Academic & Government sales.
Citing robust demand and operational strength, Waters raised full-year 2025 non-GAAP EPS guidance to $12.95–$13.05 and constant currency sales growth to 5.5%–7.5%.
CEO Udit Batra also highlighted integration plans for BD Biosciences & Diagnostic Solutions, naming Chris Ross to lead the process.
